Literature DB >> 16101732

Donor transmitted anaplastic carcinoma in a kidney-transplant recipient.

Jan D Krapp1, Robert B Brauer, Eduard Matevossian, Klaus E Gerauer, Stefan Thorban, Karin Becker, Manfred J Stangl.   

Abstract

With the more frequent use of organs from elderly donors, the risk of transmitting tumor cells to the recipient increases. We report a case in which anaplastic carcinoma tumor cells from an organ-donor were transmitted to a kidney transplantation recipient. The donor's metastatic disease was discovered 7 days after harvest of the kidney following a brain biopsy undertaken at admission of the donor. The risk of transmitting the disease was generally estimated as so small that the excellently functioning kidney was not removed. Twelve weeks later, however, malignant cells were found in a biopsy of the transplanted kidney. The organ was removed immediately, but the intraoperative situs showed advanced disease with lymph-node-metastasis. Twelve months later no tumor progress could be detected. This case shows that there is considerable risk of transmitting formerly undetected cancer in elderly donors. Autopsies of donors who are older than 60 years of age should be routinely performed after organ donation.

Entities:  

Mesh:

Year:  2005        PMID: 16101732     DOI: 10.1111/j.1432-2277.2005.00178.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Authors:  Andrew S Flies; A Bruce Lyons; Lynn M Corcoran; Anthony T Papenfuss; James M Murphy; Graeme W Knowles; Gregory M Woods; John D Hayball
Journal:  Front Immunol       Date:  2016-12-09       Impact factor: 7.561

2.  How the devil facial tumor disease escapes host immune responses.

Authors:  Hannah V Siddle; Jim Kaufman
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.